AR and breast carcinoma: Mammary gland-specific, targeted inactivation of relevant genes such as the Ar (Cre-loxP using promoters targeting mammary cells; Table?1) combined with breast cancer models are promising approaches to investigate androgenic regulation of specific pathways and effects on mammary gland pathology [32].